Belite Bio (NASDAQ:BLTE) CEO Yu-Hsin Lin Sells 365 Shares of Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CEO Yu-Hsin Lin sold 365 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total transaction of $65,827.75. Following the sale, the chief executive officer owned 170,569 shares in the company, valued at $30,762,119.15. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Belite Bio Trading Down 2.1%

Shares of NASDAQ:BLTE opened at $162.80 on Friday. Belite Bio, Inc. Sponsored ADR has a twelve month low of $60.00 and a twelve month high of $200.00. The firm has a market cap of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22. The company has a 50 day moving average of $152.50 and a 200-day moving average of $159.86.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. Equities research analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current year.

Institutional Trading of Belite Bio

Several hedge funds and other institutional investors have recently modified their holdings of BLTE. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after buying an additional 282 shares during the last quarter. Bank of America Corp DE boosted its holdings in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after purchasing an additional 257 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Belite Bio during the fourth quarter valued at about $103,000. Persistent Asset Partners Ltd bought a new stake in Belite Bio in the 4th quarter valued at $108,000. Finally, EverSource Wealth Advisors LLC bought a new position in Belite Bio during the second quarter worth about $147,000. 0.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BLTE shares. Morgan Stanley boosted their target price on Belite Bio from $201.00 to $206.00 and gave the stock an “overweight” rating in a research report on Friday. Benchmark restated a “buy” rating on shares of Belite Bio in a report on Friday. Truist Financial set a $217.00 price objective on shares of Belite Bio in a research note on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. Finally, Zacks Research raised shares of Belite Bio from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $205.80.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.